

Press release 2012-02-01

WntResearch: The lead project Foxy-5 has now been earmarked for funding from the Eurostars program.

WntResearch AB (WNT.ST) announces that its lead project Foxy-5 has now been earmarked for funding within the framework of an approved Eurostars project by the relevant National Funding Bodies. This means that the Foxy-5 is now co-funded all the way from manufacturing of the drug, through confirmatory pre-clinical studies and full regulatory tox-package to clinical phase 1 study and into the first phase 2 study in cancer patients. The Company has still not got an exact amount of the support – but will inform the market as soon as we know by the end of February 2012.

The Eurostars programme funds research and development (R&D) activities driven by Small and Medium size Entities. The EU is supporting the initiative with a €100 million grant, while an additional €300 million will come from the 27 countries which have signed up to the initiative.

VD Nils Brünner comments:

The funding is a financial break through for WntResearch and we are all eager to execute the strategy for the development of Foxy-5 as an anti-metastatic drug. I feel confident that with the present international Eurostars consortium, the competences of the Board of Directors and Management we have the ideal team for being successful. I acknowledge the foresight of Bert Junno, former CEO now CFO for having applied for the Eurostars funding.

For further information please contact:

Nils Brünner, CEO
E-mail: nbr@wntresearch.com
Telephone: +45 2614 4708

or

Peter Buhl Jensen, Chairman of the Board
E-mail: pbj@buhloncology.com
Telephone: +45 2160 8922

About WntResearch AB

WntResearch (WNT.ST) is a public company listed at the AktieTorget and is a research based Biotech Company spun out of Lund University, Sweden, founded in 2007. The focus and aim of WntResearch is to develop novel anti-metastatic therapies, in areas of unmet need, for the treatment of cancer patients. The company has two major drug development projects, Foxy-5 and Box-5. The lead project Foxy-5 is supported by the Eurostars funding program and is currently being tested in in-vivo models and planned to enter phase 1 clinical trial in 2012 in metastatic cancer.

About WntResearch AB

WntResearch (WNT.ST) is a public company listed at the AktieTorget and is a research based Biotech Company spun out of Lund University, Sweden, founded in 2007. The focus and aim of WntResearch is to develop novel anti-metastatic therapies, in areas of unmet need, for the treatment of cancer patients. The company has two major drug development projects, Foxy-5 and Box-5. The lead project Foxy-5 is supported by the Eurostars funding program and is currently being tested in in-vivo models and planned to enter phase 1 clinical trial in 2012 in metastatic cancer.